var data={"title":"Carbidopa and levodopa: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Carbidopa and levodopa: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6452?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=carbidopa-and-levodopa-patient-drug-information\" class=\"drug drug_patient\">see &quot;Carbidopa and levodopa: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187993\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Duopa;</li>\n      <li>Parcopa [DSC];</li>\n      <li>Rytary;</li>\n      <li>Sinemet;</li>\n      <li>Sinemet CR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187994\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Levocarb;</li>\n      <li>Apo-Levocarb CR;</li>\n      <li>Dom-Levo-Carbidopa;</li>\n      <li>Duodopa;</li>\n      <li>Levocarb CR;</li>\n      <li>PMS-Levocarb CR;</li>\n      <li>PRO-Levocarb;</li>\n      <li>Sinemet;</li>\n      <li>Sinemet CR;</li>\n      <li>Teva-Levocarbidopa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188007\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anti-Parkinson Agent, Decarboxylase Inhibitor;</li>\n      <li>\n        Anti-Parkinson Agent, Dopamine Precursor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187997\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parkinson disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate release tablet, orally disintegrating tablet: <b>Note:</b> Carbidopa/levodopa tablets are available in a 1:4 ratio of carbidopa to levodopa as well as 1:10 ratio. Tablets of the two ratios may be given separately or combined as needed to provide the optimum dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial: Carbidopa 25 mg/levodopa 100 mg 3 times daily (preferred) or carbidopa 10 mg/levodopa 100 mg 3 to 4 times daily (typically does not provide an adequate amount of carbidopa for most patients)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients previously treated with levodopa &lt;1,500 mg daily: Carbidopa 25 mg/levodopa 100 mg 3 or 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients previously treated with levodopa &gt;1,500 mg daily: Carbidopa 25 mg/levodopa 250 mg 3 or 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note: </b>Discontinue levodopa at least 12 hours before starting therapy with carbidopa/levodopa. Substitute the combination drug at a dosage that will provide approximately 25% of the previous levodopa dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosage adjustment: Alternate tablet strengths may be substituted according to individual carbidopa/levodopa requirements. Use of more than 1 dosage strength or dosing 4 times daily may be required (maximum: 8 tablets of any strength daily or 200 mg of carbidopa and 2,000 mg of levodopa)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Carbidopa 10 mg/levodopa 100 mg: Increase by 1 tablet daily or every other day, as necessary, to 2 tablets 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Carbidopa 25 mg/levodopa 100 mg: Increase by 1 tablet daily or every other day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Carbidopa 25 mg/levodopa 250 mg: Increase by <sup>1</sup>/<sub>2</sub> or 1 tablet daily or every other day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Controlled-release tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients not currently receiving levodopa: Initial: Carbidopa 50 mg/levodopa 200 mg 2 times daily, at intervals not &lt;6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients currently receiving levodopa: <b>Note:</b> Discontinue levodopa at least 12 hours before starting carbidopa/levodopa therapy. Initial: Substitute at a dosage that will provide approximately 25% of the previous levodopa dosage; usual initial dose in mild to moderate disease is carbidopa 50 mg/levodopa 200 mg 2 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients converting from immediate-release formulation to controlled release: Initial: Dosage should be substituted at an amount that provides ~10% more of levodopa/day; total calculated dosage is administered in divided doses 2 to 3 times/day (or &ge;3 times/day for patients maintained on levodopa &ge;700 mg). Intervals between doses should be 4 to 8 hours while awake; when divided doses are not equal, smaller doses should be given toward the end of the day. Depending on clinical response, dosage may need to be increased to provide up to 30% more levodopa/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosage adjustment: May adjust every 3 days; intervals should be &gt;4 hours during the waking day (maximum dose: 8 tablets/day)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release capsule: <b>Note:</b> Carbidopa/levodopa extended-release capsules are <b>not</b> interchangeable with other carbidopa/levodopa products.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients not currently receiving levodopa: Initial: Carbidopa 23.75 mg/levodopa 95 mg 3 times daily for 3 days; on day 4, increase to carbidopa 36.25 mg/levodopa 145 mg 3 times daily. May increase dose up to carbidopa 97.5 mg/levodopa 390 mg 3 times a day; frequency of dosing may be increased to a maximum of 5 times daily if needed and tolerated (maximum: carbidopa 612.5 mg/levodopa 2,450 mg per day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients converting from immediate-release formulation to extended-release capsules: Initial: Initial dose based off of total current daily dose of levodopa in immediate-release carbidopa/levodopa as follows (frequency of dosing may be increased to a maximum of 5 times daily if needed and tolerated):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If total daily dose of levodopa is between 400 mg to 549 mg: 3 capsules of carbidopa 23.75 mg/levodopa 95 mg 3 times daily (levodopa total daily dose: 855 mg).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If total daily dose of levodopa is between 550 mg to 749 mg: 4 capsules of carbidopa 23.75 mg/levodopa 95 mg 3 times daily (levodopa total daily dose: 1,140 mg).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If total daily dose of levodopa is between 750 mg to 949 mg: 3 capsules of carbidopa 36.25 mg/levodopa 145 mg 3 times daily (levodopa total daily dose: 1,305 mg).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If total daily dose of levodopa is between 950 mg to 1249 mg: 3 capsules of carbidopa 48.75 mg/levodopa 195 mg 3 times daily (levodopa total daily dose: 1,755 mg).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If total daily dose of levodopa is &ge;1,250 mg: 4 capsules of carbidopa 48.75 mg/levodopa 195 mg 3 times daily (levodopa total daily dose: 2,340 mg) or 3 capsules of carbidopa 61.25/levodopa 245 mg 3 times daily (levodopa total daily dose: 2,205 mg).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosage adjustment: Adjust dose as needed (maximum dose: carbidopa 612.5 mg/levodopa 2,450 mg per day).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Concomitant therapy: For patients currently treated with carbidopa/levodopa plus catechol-O-methyl transferase (COMT) inhibitors (eg, entacapone), the initial total daily dose of carbidopa/levodopa may need to be increased. Use of carbidopa/levodopa extended-release capsules in combination with other levodopa products has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intestinal infusion via PEG-J tube:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intestinal suspension (Duopa): Initial: <b>Note:</b> Prior to initiation of therapy, convert patients from all forms of levodopa to oral immediate-release carbidopa/levodopa tablets (1:4 ratio). Total daily dose (expressed in terms of levodopa) consists of a morning dose, a continuous dose and extra doses. Maximum dose is 2,000 mg of the levodopa component (ie, one cassette per day) over 16 hours. Patients should receive their routine night-time dosage of oral immediate-release carbidopa/levodopa after discontinuation of daily infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Morning dose and continuous dose: Refer to manufacturer&rsquo;s labeling for morning dose and continuous dose calculations and titration instructions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extra doses: Can be used to manage acute &quot;off&quot; symptoms that are not controlled by the morning and continuous dose. Set extra dose function at 1 mL (20 mg of levodopa) initially; adjust in 0.2 mL increments if needed. Maximum: One extra dose every 2 hours. <b>Note:</b> Frequent extra doses may cause or worsen dyskinesias.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Discontinuation: Avoid sudden discontinuation or rapid dose reduction; taper dose or switch patients to oral immediate-release carbidopa-levodopa.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intestinal gel (Duodopa [Canadian product]): <b>Note:</b> Conversion to/from oral levodopa tablet formulations and the intestinal gel formulation can be done on a 1:1 ratio. Total daily dose (expressed in terms of levodopa) consists of a morning bolus dose, a continuous maintenance dose, and additional bolus doses when necessary. Nighttime dosing may be necessary in certain rare situations (eg, nocturnal akinesia). Dosage adjustments should be carried out over a period of a few weeks. Patients should receive their routine night-time dosage of oral levodopa/carbidopa after discontinuation of daily infusion</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Morning bolus dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 1: Based on a percentage of the previous morning levodopa intake and volume to fill intestinal tubing:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Previous morning dose of levodopa &le;200 mg: Administer Duodopa at 80% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Previous morning dose of levodopa 201 to 399 mg: Administer Duodopa at 70% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Previous morning dose of levodopa &ge;400 mg: Administer Duodopa at 60% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Day 2 and beyond till dose is stable: Adjust dose based on response to the previous morning levodopa intake and volume to fill intestinal tubing): Usual: Levodopa 100 to 200 mg (5 to 10 mL); Maximum: Levodopa 300 mg (15 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous maintenance dose: Adjustable in increments of 2 mg/hour (0.1 mL/hour) and based on previous daily intake of levodopa: Usual: Levodopa 40 to 120 mg/hour (2 to 6 mL/hour) infused up to 16 hours; Range: Levodopa 20 to 200 mg/hour (1 to 10 mL/hour). Higher doses may be necessary in exceptional cases.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Additional bolus doses: Usual: Levodopa: 10 to 40 mg (0.5 to 2 mL), if needed for rapid deterioration of motor functions (eg, hypokinesia); may give additional doses hourly until stable dose is established then give every 2 hours as needed. In patients requiring &gt;5 additional boluses/day, consider increasing the maintenance dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Restless legs syndrome (RLS) (off-label use; Silber, 2004):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release tablet: Carbidopa 25 mg/levodopa 100 mg (0.5 to 1 tablet) given in the evening, at bedtime, or upon waking during the night with RLS symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Controlled-release tablet: Carbidopa 25 mg/levodopa 100 mg (1 tablet) before bedtime for RLS symptoms that awaken patient during the night</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187998\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10909896\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10909895\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27102717\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Intestinal suspension (Duopa):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dyskinesias or levodopa-related adverse reactions within 1 hour of morning dose on preceding day: Decrease morning dose by 1 mL.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dyskinesias or adverse reactions lasting &ge;1 hour on the preceding day: Decrease the continuous dose by 0.3 mL per hour.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dyskinesias or adverse reactions lasting for 2 or more periods of &ge;1 hour on the preceding day: Decrease the continuous dose by 0.6 mL per hour.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187974\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rytary:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">23.75/95: Carbidopa 23.75 mg and levodopa 95 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">36.25/145: Carbidopa 36.25 mg and levodopa 145 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">48.75/195: Carbidopa 48.75 mg and levodopa 195 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">61.25/245: Carbidopa 61.25 mg and levodopa 245 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Enteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Duopa:  Carbidopa 4.63 mg and levodopa 20 mg per 1 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sinemet:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">10/100: Carbidopa 10 mg and levodopa 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">25/100: Carbidopa 25 mg and levodopa 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">25/250: Carbidopa 25 mg and levodopa 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10/100: Carbidopa 10 mg and levodopa 100 mg; 25/100: Carbidopa 25 mg and levodopa 100 mg; 25/250: Carbidopa 25 mg and levodopa 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sinemet CR:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">25/100: Carbidopa 25 mg and levodopa 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">50/200: Carbidopa 50 mg and levodopa 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25/100: Carbidopa 25 mg and levodopa 100 mg; 50/200: Carbidopa 50 mg and levodopa 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, orally disintegrating: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Parcopa:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">10/100: Carbidopa 10 mg and levodopa 100 mg [contains phenylalanine 3.4 mg/tablet; mint flavor] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">25/100: Carbidopa 25 mg and levodopa 100 mg [contains phenylalanine 3.4 mg/tablet; mint flavor] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">25/250: Carbidopa 25 mg and levodopa 250 mg [contains phenylalanine 8.4 mg/tablet; mint flavor] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10/100: Carbidopa 10 mg and levodopa 100 mg; 25/100: Carbidopa 25 mg and levodopa 100 mg; 25/250: Carbidopa 25 mg and levodopa 250 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187958\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes, excludes extended release capsule and enteral suspension</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10909903\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intestinal gel:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Duodopa: Carbidopa 5 mg and levodopa 20 mg/1 mL (100 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11236626\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Duodopa intestinal gel [Canadian product]:</b> In Canada, the Duodopa Education Program is a risk mitigation program established to provide safe and effective use of Duodopa in advanced Parkinson patients. The program involves:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">- Education of prescribing neurologists and other health care providers on suitable candidates for treatment, surgical procedures (PEG tube placement), and follow-up care including infusion device education.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">- Distribution of educational materials to patients and caregivers describing Duodopa intestinal gel and its proper use, PEG tube placement, and complications associated with the mode of administration and/or PEG tube placement.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187978\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intestinal suspension (Duopa): Remove one cassette from refrigerator 20 minutes prior to use (failure to use at room temperature may result in inaccurate dosage). Administer as a 16-hour infusion through either a naso-jejunal tube (temporary administration) or through a percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube (long-term administration) connected to the CADD-Legacy 1400 pump. At the end of administration, disconnect the tube from the pump at the end of the infusion and flush with room-temperature drinking water with a syringe. Following discontinuation of the daily infusion, patients should administer their routine night-time dosage of oral immediate-release carbidopa/levodopa. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intestinal gel (Duodopa [Canadian product]): Gel is administered directly to the jejunum via a portable infusion pump (CADD-legacy Duodopa pump). Administer through a temporary nasojejunal tube for a short-term test period to evaluate patient response and for dose optimization. Long-term administration requires placement of PEG-J tube for intestinal infusion. Continuous maintenance dose is infused throughout the day for up to 16 hours if necessary, may administer at night (eg, nocturnal akinesia).  Disconnect PEG-J tube from infusion pump at end of infusion and flush with room temperature water to prevent occlusion of tubing.  Following  discontinuation of the daily infusion, patients should administer their routine night-time dosage of oral levodopa/carbidopa.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extended-release capsule: Administer with or without food; a high-fat, high-calorie meal may delay the absorption of levodopa by ~2 hours. Swallow capsules whole; do not chew, divide, or crush capsules. Patients who have difficulty swallowing intact capsules may open the capsule, sprinkle entire contents on a small amount of applesauce (1 to 2 tablespoons) and consume immediately (do not store for future use).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral tablet formulations: Space doses evenly over the waking hours. Administer with meals to decrease GI upset. Controlled release product should not be chewed or crushed. Orally disintegrating tablets do not require water; the tablet should disintegrate on the tongue's surface before swallowing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187977\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Parkinson disease:</b> Treatment of Parkinson disease, postencephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide and/or manganese intoxication; treatment of motor fluctuations in advanced Parkinson disease (intestinal suspension [Duopa] only).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25722063\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Restless leg syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6842204\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Sinemet may be confused with Janumet, Serevent</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zimox: Brand name for carbidopa and levodopa [Greece], but also the brand name for amoxicillin [Italy]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zimox [Greece] may be confused with Diamox which is a brand name for acetazolamide [Canada and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187965\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Orthostatic hypotension (&le;73%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (6% to 19%), headache (13% to 17%; oral 1% to 5%), depression (with or without suicidal tendencies; Duopa 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (3% to 30%), constipation (&le;22%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Erythema at injection site (Duopa 19%), application site discharge (Duopa 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Dyskinesia (12% to 17%; Rytary 2% to 5%; including choreiform, dystonic and other involuntary movements), increased creatine phosphokinase (&le;17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen (&le;13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Procedural complications (from device insertion: Duopa 57%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (Duopa 8%), hypertension (&le;8%), ischemia (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Insomnia (6% to 9%), anxiety (2% to 8%), confusion (2% to 8%), abnormal dreams (2% to 6%), polyneuropathy (Duopa 5%), sleep disorder (Duopa 5%), hallucination (1% to 5%), psychosis (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Wound healing impairment (excessive granulation tissue; Duopa 5%), skin rash (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Hiatal hernia (6% to 8%), xerostomia (7%), intestinal obstruction (Duopa 5%), diarrhea (&le;5%), dyspepsia (&le;5%), ileus (&le;5%), vomiting (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Bacteriuria (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukocyturia (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Atelectasis (Duopa 8%), oropharyngeal pain (Duopa 8%), upper respiratory tract infection (Duopa 8%; Sinemet and Sinemet CR &le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac arrhythmia, chest pain, edema, flushing, hypotension, myocardial infarction, palpitations, phlebitis, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Abnormal behavior, abnormal gait, abnormality in thinking, agitation, ataxia, decreased mental acuity, delirium, delusions, dementia, disorientation, drowsiness, euphoria, extrapyramidal reaction, falling, fatigue, glossopyrosis, Horner syndrome (reactivation), impulse control disorder, malaise, memory impairment, narcolepsy, nervousness, neuroleptic malignant syndrome, nightmares, numbness, on-off phenomenon, pain (naso-jejunal insertion), paranoia, paresthesia, pathological gambling, peripheral neuropathy, seizure (causal relationship not established), trismus</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia, diaphoresis, discoloration of sweat</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Abnormal alanine aminotransferase, abnormal alkaline phosphatase, abnormal aspartate transaminase, abnormal lactate dehydrogenase, glycosuria, hot flash, hyperglycemia, hypokalemia, increased libido (including hypersexuality), increased uric acid, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distention (PEG-J and naso-jejunal insertion), abdominal distress (PEG-J and naso-jejunal insertion), abdominal pain (PEG-J and naso-jejunal insertion), anorexia, bruxism, discoloration of saliva, duodenal ulcer (PEG-J and naso-jejunal insertion), duodenitis (erosive, PEG-J and naso-jejunal insertion), dysgeusia, dysphagia (naso-jejunal insertion), esophageal hemorrhage (naso-jejunal insertion), flatulence (PEG-J insertion), gastritis (erosive; PEG-J and naso-jejunal insertion), gastrointestinal hemorrhage (PEG-J and naso-jejunal insertion), heartburn, hiccups, intussusception (PEG-J and naso-jejunal insertion), peritonitis (PEG-J and naso-jejunal insertion), sialorrhea, sore throat (naso-jejunal insertion), upper abdominal pain (PEG-J and naso-jejunal insertion)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Difficulty in micturition, priapism, proteinuria, urinary frequency, urinary incontinence, urinary retention, urinary tract infection, urine discoloration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Agranulocytosis, anemia, decreased hematocrit, decreased hemoglobin, hemolytic anemia, IgA vasculitis, leukopenia, malignant melanoma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal bilirubin levels</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (angioedema, bullous lesions [including pemphigus-like reactions], pruritus, urticaria)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Abnormal Coombs test</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Abscess (postoperative; PEG-J and naso-jejunal insertion)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain, excessive tremors, leg pain, muscle cramps, muscle twitching, shoulder pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blepharospasm, blurred vision, diplopia, glaucoma, increased intraocular pressure, mydriasis, oculogyric crisis (may be associated with acute dystonic reactions)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, dyspnea, hoarseness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Thrombocytopenia (Lee 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187981\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to levodopa, carbidopa, or any component of the formulation; concurrent use with nonselective monoamine oxidase inhibitors (MAOIs) or use within the last 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Additional contraindications: Narrow angle glaucoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Clinical or laboratory evidence of uncompensated cardiovascular, endocrine, hepatic, hematologic or pulmonary disease (eg, including bronchial asthma), or renal disease; when administration of a sympathomimetic amine (eg, epinephrine, norepinephrine, isoproterenol) is contraindicated; in the presence of a suspicious, undiagnosed skin lesion or history of melanoma; intestinal gel therapy in patients with any condition preventing the required placement of a PEG tube for administration (ie, pathological changes of gastric wall, inability to bring gastric and abdominal wall together, blood coagulation disorders, peritonitis, acute pancreatitis, paralytic ileus).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187962\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abnormal thinking/behavioral changes: Abnormal thinking and behavior changes have been reported and may include aggressive behavior, agitation, confusion, delirium, delusions, disorientation, paranoid ideation, and psychotic-like behavior.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dyskinesias: May cause or exacerbate dyskinesias; may require dosage reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hallucinations: Hallucinations may occur and be accompanied by confusion and to a lesser extent sleep disorder and excessive dreaming; typically presents shortly after initiation of therapy and may require dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Impulse control disorders: Dopamine agonists used for Parkinson disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, increased sexual urges, intense urges to spend money, binge or compulsive eating, and/or other intense urges. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Melanoma: Risk for melanoma development is increased in Parkinson disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome: A symptom complex resembling neuroleptic malignant syndrome (NMS) has been reported in association with rapid dose reduction, or abrupt withdrawal. Identification of more severe NMS-like reactions (eg, altered consciousness, hyperthermia, involuntary movements, muscle rigidity, autonomic instability, mental status changes) can be complex; monitor patients closely for this reaction and when the dosage of levodopa is reduced abruptly or discontinued. Discontinue treatment immediately if signs/symptoms arise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension; Parkinson disease patients appear to have an impaired capacity to respond to a postural challenge. Use with caution in patients at risk of hypotension (such as those receiving antihypertensive drugs) or where transient hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). Parkinson patients being treated with dopaminergic agonists ordinarily require careful monitoring for signs and symptoms of postural hypotension, especially during dose escalation, and should be informed of this risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Somnolence: Somnolence and falling asleep while engaged in activities of daily living (including operation of motor vehicles) have been reported; some cases reported that there were no warning signs for the onset of symptoms. Symptom onset may occur well after initiation of treatment; some events have occurred more than 1 year after start of therapy. Prior to treatment initiation, evaluate for factors that may increase these risks such as concomitant sedating medications, and the presence of sleep disorders. Monitor for drowsiness or sleepiness. If significant daytime sleepiness or episodes of falling asleep during activities that require active participation occurs (eg, driving, conversations, eating), discontinue the medication. There is insufficient information to suggest that dose reductions will eliminate these symptoms. If therapy is continued, advise patient to avoid driving and other potentially dangerous activities.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with severe cardiovascular disease, including a history of myocardial infarction who have residual atrial, nodal, or ventricular arrhythmias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Endocrine disease: Use with caution in patients with endocrine disease and when interpreting plasma/urine catecholamine levels; falsely diagnosed pheochromocytoma has been rarely reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use with caution in patients with glaucoma; monitor IOP carefully; some formulations are contraindicated in patients with narrow-angle glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropathy: Peripheral neuropathy has been reported with use; prior to initiation, evaluate patients for history of neuropathy and known risk factors (eg, deficiency of vitamin B<sub>6</sub> and/or B<sub>12</sub>, diabetes mellitus, hypothyroidism). Assess patients for peripheral neuropathy periodically during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peptic ulcer disease: Oral products: Use with caution in patients with a history of peptic ulcer disease; risk of GI hemorrhage may be increased.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychotic disorders: Avoid use in patients with a major psychotic disorder. Use with extreme caution in patients with psychotic disorders because of the risk of exacerbating psychosis; observe patients closely for development of depression with concomitant suicidal tendencies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; may be more sensitive to CNS effects (eg, hallucinations) of levodopa.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage forms specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intestinal suspension (Duopa): GI complications (eg, bezoar, ileus, implant-site erosion/ulcer, intestinal hemorrhage, intestinal ischemia, intestinal obstruction, intestinal perforation, pancreatitis, peritonitis, pneumoperitoneum, postoperative wound infection) may occur (may be fatal). Patients should notify their health care provider immediately if abdominal pain, prolonged constipation, nausea, vomiting, fever, and/or melanotic stool occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intestinal gel (Duodopa [Canadian product]): Product should be prescribed only by neurologists experienced in the treatment of Parkinson disease and who have completed the Duodopa Education Program. Response to levodopa/carbidopa intestinal gel therapy should be assessed with a short-term test period of administration via a temporary nasojejunal tube prior to placement of a percutaneous endoscopic gastrostomy-jejunostomy (PEG-J) tube for permanent access and administration. Sudden deterioration in therapy response with recurring motor symptoms may indicate PEG-J tube complications (eg, displacement) or obstruction of the infusion device. Tube or infusion device complications may require initiation of oral levodopa/carbidopa therapy until complications are resolved.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Body fluid discoloration: Urine, saliva, or sweat may appear dark in color (red, brown, black) during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dietary protein: Distribute dietary protein throughout the day to avoid fluctuations in levodopa absorption. A high-protein diet may reduce the effectiveness of the enteral formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome on abrupt withdrawal, rapid dose reduction, significant dosage reduction after long-term use, or changes in dopaminergic therapy. Avoid sudden discontinuation or rapid dose reduction; taper dose to reduce the risk of hyperpyrexia and confusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298971\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187967\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8994&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Amisulpride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (First Generation [Typical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Biperiden: May enhance the adverse/toxic effect of Levodopa. Specifically, the risk of choreic movements or dyskinesias may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Levodopa.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: Anti-Parkinson Agents (Dopamine Agonist) may enhance the adverse/toxic effect of BuPROPion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droxidopa: Carbidopa may diminish the therapeutic effect of Droxidopa. Carbidopa may decrease serum concentrations of the active metabolite(s) of Droxidopa. Carbidopa may increase the serum concentration of Droxidopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May diminish the therapeutic effect of Levodopa.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Systemic): May decrease the serum concentration of Levodopa.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Levodopa. Only applies to oral iron preparations. Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: May diminish the therapeutic effect of Levodopa.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Levodopa may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methionine: May diminish the therapeutic effect of Levodopa. Probably only with large doses of methionine.  Data was generated using 4.5gm daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: Levodopa may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.  Management: The concomitant use of nonselective monoamine oxidase inhibitors (MAOIs) and levodopa is contraindicated. Discontinue the nonselective MAOI at least two weeks prior to initiating levodopa. Monitor patients taking a selective MAOIs and levodopa.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): May diminish the therapeutic effect of Levodopa. Specifically, pyridoxine may diminish the effects of levodopa, when used in the absence of a dopa decarboxylase inhibitor. Management: Concurrent use of a multivitamin and levodopa (without carbidopa) should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May diminish the therapeutic effect of Levodopa. Multivitamins/Minerals (with ADEK, Folate, Iron) may decrease the serum concentration of Levodopa. Only applies to oral iron-containing preparations. Management: Separate doses of these agents by 2 or more hours.  Monitor for decreased levodopa effects, particularly if doses cannot be separated.  Concurrent use of a multivitamin and levodopa (without carbidopa) should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May diminish the therapeutic effect of Levodopa. Specifically, pyridoxine may diminish the effects of levodopa, when used in the absence of a dopa decarboxylase inhibitor. Management: Concurrent use of a multivitamin and levodopa (without carbidopa) should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Papaverine: May enhance the hypotensive effect of Levodopa. Papaverine may diminish the therapeutic effect of Levodopa.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May diminish the therapeutic effect of Levodopa.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyridoxine: May diminish the therapeutic effect of Levodopa. Management: The concomitant use of pyridoxine and levodopa (in the absence of a dopa decarboxylase inhibitor (DDI)) should be avoided. Use of a DDI (e.g., carbidopa) with levodopa will essentially eliminate the risk of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sapropterin: May enhance the adverse/toxic effect of Levodopa.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spiramycin: May decrease the serum concentration of Carbidopa. And thus may decrease the effectiveness of levodopa.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187990\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">High protein diets have the potential to impair levodopa absorption; levodopa competes with certain amino acids for transport across the gut wall or across the blood-brain barrier. Management: Avoid high protein diets. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187970\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187985\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies using this combination. Carbidopa can be detected in the umbilical cord, but absorption in fetal tissue is minimal. Levodopa crosses the placenta and can be metabolized by the fetus and detected in fetal tissue (Merchant 1995). The incidence of Parkinson disease in pregnancy is relatively rare, and information related to the use of carbidopa/levodopa in pregnant women is limited (Ball 1995; Cook 1985; Golbe 1987; Serikawa 2011; Shulman 2000). Current guidelines note that the available information is insufficient to make a recommendation for the treatment of restless legs syndrome in pregnant women (Aurora 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21737065\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Levodopa is excreted in breast milk. A study was done in one lactating woman at 4.5 months postpartum who had been taking carbidopa/levodopa for several years. Regardless of the formulation (sustained release or immediate release) peak levodopa concentrations in the breast milk were found ~3 hours after the maternal dose and returned to baseline ~6 hours after the dose. The highest milk concentration (3.47 nmol/L) was found following the immediate-release tablet and this was 27% of the peak maternal plasma concentration (occurring 30 minutes after the dose) and ~40% of the simultaneous plasma concentration. Carbidopa was not evaluated (Thulin 1998). The manufacturer recommends that caution be exercised when administering carbidopa/levodopa to nursing women. Use of Duodopa intestinal gel [Canadian product] in nursing women is not recommended by the manufacturer (Duodopa Canadian product labeling 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187986\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid high protein diets (&gt;2 g/kg) which may decrease the efficacy of levodopa via competition with amino acids in crossing the blood-brain barrier. Some products may contain phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187972\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs and symptoms of Parkinson disease; periodic hepatic function tests, BUN, creatinine, and CBC; periodic skin examinations; blood pressure, standing and sitting/supine; symptoms of dyskinesias, mental status changes; cardiac function (particularly during initial dosage adjustment), IOP (in patients with glaucoma); signs and symptoms of neuroleptic malignant syndrome if abrupt discontinuation required (as with surgery); drowsiness or sleepiness; signs of depression (including suicidal thoughts); signs and symptoms of peripheral neuropathy prior to therapy and periodically during therapy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Additional Canadian labeling recommendations include vitamin B<sub>12</sub>, vitamin B<sub>6</sub>, folic acid, homocysteine, and methylmalonic acid levels prior to initiation and regularly thereafter (Duodopa Canadian product monograph).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187961\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Parkinson disease symptoms are due to a lack of striatal dopamine; levodopa circulates in the plasma to the blood-brain-barrier (BBB), where it crosses, to be converted by striatal enzymes to dopamine; carbidopa inhibits the peripheral plasma breakdown of levodopa by inhibiting its decarboxylation, and thereby increases available levodopa at the BBB</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187980\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Absorption of levodopa may be decreased with high-fat, high-calorie or high-protein meal.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Levodopa: 0.9 to 1.6 L/kg (in presence of carbidopa), crosses the blood-brain barrier; Carbidopa: Does not cross the blood-brain barrier</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Levodopa has two major pathways (decarboxylation and O-methylation) and two minor pathways (transamination and oxidation) of metabolism; Carbidopa inhibits the decarboxylation of levodopa to dopamine in the peripheral tissue to allow greater levodopa distribution into the CNS </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Controlled and extended release: Levodopa: Bioavailability is ~70% to 75% relative to availability from immediate release formulation; Carbidopa: Bioavailability is ~50% to 58% relative to availability from immediate release formulation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intestinal gel [Canadian product]: Levodopa: Similar bioavailability relative to oral administration of tablet formulations (81% to 98%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intestinal suspension: Levodopa: 97% relative to oral immediate release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Immediate release: Levodopa (in presence of carbidopa): 1.5 hours; Half-life may be prolonged with controlled and extended release formulations due to continuous absorption</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Immediate release: 0.5 hours; Controlled and extended release: 2 hours; Intestinal gel [Canadian product]: Therapeutic plasma levels reached 10 to 30 minutes following morning bolus dose; Intestinal suspension: 2.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187984\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, controlled release</b> (Rytary Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">23.75-95 mg (100): $318.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">36.25-145 mg (100): $318.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">48.75-195 mg (100): $318.49</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">61.25-245 mg (100): $400.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Duopa Enteral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.63-20 mg/mL (100 mL): $242.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Carbidopa-Levodopa ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25-100 mg (100): $93.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50-200 mg (100): $180.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Sinemet CR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25-100 mg (100): $175.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50-200 mg (100): $336.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Carbidopa-Levodopa Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-100 mg (100): $121.48</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25-100 mg (100): $137.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25-250 mg (100): $174.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Carbidopa-Levodopa Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-100 mg (100): $77.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25-100 mg (100): $80.02</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25-250 mg (100): $94.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sinemet Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10-100 mg (100): $139.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25-100 mg (100): $157.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25-250 mg (100): $199.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187987\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aldopa (BD);</li>\n      <li>Apo-Levotard (MY);</li>\n      <li>Apodespan (IE);</li>\n      <li>Bidopar (TW);</li>\n      <li>Carbidol (BR);</li>\n      <li>Carbilev (ZA);</li>\n      <li>Cardopar (SG);</li>\n      <li>Carlevod (AR);</li>\n      <li>Cinemet CR (BD);</li>\n      <li>Credanil (MT);</li>\n      <li>Dopadura (DE);</li>\n      <li>Dopicar (IL);</li>\n      <li>Duodopa (AU, HR, IL, JP, RO, TH);</li>\n      <li>DuoDopa (BE, GB, IE);</li>\n      <li>Enpalevo (TW);</li>\n      <li>Grifoparkin (CL, PE);</li>\n      <li>Half Sinemet (IE);</li>\n      <li>Istonil (PY);</li>\n      <li>Kinson (AU);</li>\n      <li>Lavida (PH);</li>\n      <li>Lebocar (AR);</li>\n      <li>Ledocar (PH);</li>\n      <li>Levocar (JO);</li>\n      <li>Levomed (MY);</li>\n      <li>Levomet (HK, SG, TH);</li>\n      <li>Levopa (BD);</li>\n      <li>Nakom (EE, HR, PL, RO, RU, SI, SK);</li>\n      <li>Pardopa (IN);</li>\n      <li>Parken (CO);</li>\n      <li>Parkimet (PH);</li>\n      <li>Parkimet CR (PH);</li>\n      <li>Parkomet (AE, BH, CY, EG, IQ, IR, JO, KW, LY, OM, QA, SY, YE);</li>\n      <li>Perkin (KR);</li>\n      <li>Racovel (MX);</li>\n      <li>Saniter (CL);</li>\n      <li>Sindopa (NZ);</li>\n      <li>Sinedin (PH);</li>\n      <li>Sinedopa (HK, MY);</li>\n      <li>Sinedopa Mite (MY);</li>\n      <li>Sinemet (AT, AU, BB, BE, BR, CH, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, IE, IS, IT, JO, KR, KW, LB, LT, MT, MX, MY, NI, NL, NO, NZ, PA, PK, PL, PT, PY, QA, RU, SA, SE, SK, SV, TH, TR, TW, UY, VE);</li>\n      <li>Sinemet 25 100 (HK, MY, PH);</li>\n      <li>Sinemet CR (AU, BB, BE, BG, CH, CN, CR, CY, CZ, DO, GB, GR, GT, HK, HN, IL, IT, KR, KW, LT, MY, NI, NL, NZ, PA, PE, PH, PT, QA, SV);</li>\n      <li>Sinemet Retard (ES);</li>\n      <li>Sulconar (PE);</li>\n      <li>Syndopa (BD, VN);</li>\n      <li>Tidomet (PH, TH);</li>\n      <li>Tidomet CR (PH);</li>\n      <li>Tidomet Forte (IN);</li>\n      <li>Tidomet L.S. (IN);</li>\n      <li>Tidomet Plus (IN);</li>\n      <li>Vedilma (VN);</li>\n      <li>Wendica (VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aurora RN, Kristo DA, Bista SR, et al, &quot;The Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder in Adults-An Update for 2012: Practice Parameters With an Evidence-Based Systematic Review and Meta-analyses: An American Academy of Sleep Medicine Clinical Practice Guideline,&quot; <i>Sleep</i>, 2012, 35(8):1039-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/22851801/pubmed\" target=\"_blank\" id=\"22851801\">22851801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ball MC and Sagar HJ, &quot;Levodopa in Pregnancy,&quot; <i>Mov Disord</i>, 1995, 10(1):115.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/7885346/pubmed\" target=\"_blank\" id=\"7885346\">7885346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cook DG and Klawans HL, &quot;Levodopa During Pregnancy,&quot; <i>Clin Neuropharmacol</i>, 1985, 8(1):93-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/3978654/pubmed\" target=\"_blank\" id=\"3978654\">3978654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Devos D, &ldquo;Patient Profile, Indications, Efficacy and Safety of Duodenal Levodopa Infusion in Advanced Parkinson&rsquo;s Disease,&rdquo; <i>Mov Disord</i>, 2009, 24(7):993-1000.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/19253412/pubmed\" target=\"_blank\" id=\"19253412\">19253412</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duodopa (carbidopa/levodopa intestinal gel) [product monograph]. St. Laurent, Quebec, Canada: AbbVie Corporation; February 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duopa (carbidopa and levodopa) [prescribing information]. North Chicago, IL: AbbVie Inc; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duopa (carbidopa and levodopa) [prescribing information]. North Chicago, IL: AbbVie Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Factor SA, &ldquo;Current Status of Symptomatic Medical Therapy in Parkinson&rsquo;s Disease,&rdquo; <i>Neurotherapeutics</i>, 2008, 5(2):164-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/18394561/pubmed\" target=\"_blank\" id=\"18394561\">18394561</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Golbe LI, &quot;Parkinson's Disease and Pregnancy,&quot; <i>Neurology</i>, 1987, 37(7):1245-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/3601093/pubmed\" target=\"_blank\" id=\"3601093\">3601093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee K, Kang H, Yu H, et al. Thrombocytopenia associated with Levadopa Treatment. <i>Journal of Movement Disorder</i>. 2013;6:21-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/24868421/pubmed\" target=\"_blank\" id=\"24868421\">24868421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Merchant CA, Cohen G, Mytilineou C, et al, &quot;Human Transplacental Transfer of Carbidopa/Levodopa,&quot; <i>J Neural Transm Park Dis Dement Sect</i>, 1995, 9(2-3):239-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/8527007/pubmed\" target=\"_blank\" id=\"8527007\">8527007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molina JA, S&agrave;inz-Artiga MJ, Fraile A, et al, &ldquo;Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,&rdquo; <i>Mov Disord</i>, 2000, 15(5):869-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/11009192/pubmed\" target=\"_blank\" id=\"11009192\">11009192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Olanow CW, Watts RL, and Koller WC, &ldquo;An Algorithm (Decision Tree) for the Management of Parkinson's Disease (2001): Treatment Guidelines,&rdquo; <i>Neurology</i>, 2001, 56(11 Suppl 5):1-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/11402154/pubmed\" target=\"_blank\" id=\"11402154\">11402154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rytary (carbidopa and levodopa) [prescribing information]. Hayward, CA: Impax Pharmaceuticals; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Serikawa T, Shimohata T, Akashi M, et al, &quot;Successful Twin Pregnancy in a Patient With Parkin-Sssociated Autosomal Recessive Juvenile Parkinsonism,&quot; <i>BMC Neurol</i>, 2011, 11:72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/21682904/pubmed\" target=\"_blank\" id=\"21682904\">21682904</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman LM, Minagar A, and Weiner WJ, &quot;The Effect of Pregnancy in Parkinson's Disease,&quot; <i>Mov Disord</i>, 2000, 15(1):132-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/10634252/pubmed\" target=\"_blank\" id=\"10634252\">10634252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15244390\"></a>Silber MH, Ehrenberg BL, Allen RP, et al, &ldquo;An Algorithm for the Management of Restless Legs Syndrome,&rdquo; <i>Mayo Clin Proc</i>, 2004, 79(7):916-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/15244390/pubmed\" target=\"_blank\" id=\"15244390\">15244390</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinemet (carbidopa/levodopa) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinemet (carbidopa/levodopa) [product monograph]. Kirkland, Quebec, Canda: Merck Canada Inc; Februay 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinemet CR (carbidopa/levodopa extended release tablets) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co Inc; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinemet CR ((carbidopa/levodopa extended release tablets) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; February 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stern MB, &ldquo;Contemporary Approaches to the Pharmacotherapeutic Management of Parkinson's Disease: An Overview,&rdquo; <i>Neurology</i>, 1997, 49(1 Suppl 1):2-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/9222162/pubmed\" target=\"_blank\" id=\"9222162\">9222162</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thulin PC, Woodward WR, Carter JH, et al, &quot;Levodopa in Human Breast Milk: Clinical Implications,&quot; <i>Neurology</i>, 1998, 50(6):1920-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/9633767/pubmed\" target=\"_blank\" id=\"9633767\">9633767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walker SW, Fina A, and Kryger MH, &ldquo;L-Dopa/Carbidopa for Nocturnal Movement Disorders in Uremia,&rdquo; <i>Sleep</i>, 1996, 19(3):214-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/8723378/pubmed\" target=\"_blank\" id=\"8723378\">8723378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weintraub D, Siderowf AD, Potenza MN, et al, &ldquo;Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease,&rdquo; <i>Arch Neurol</i>, 2006, 63(7):969-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/16831966/pubmed\" target=\"_blank\" id=\"16831966\">16831966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vignatelli L, Billiard M, Clarenbach P, et al, &ldquo;EFNS Guidelines on Management of Restless Leg Syndrome and Periodic Limb Movement Disorder in Sleep,&rdquo; <i>Eur J Neurol</i>, 2006, 13(10):1049-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carbidopa-and-levodopa-drug-information/abstract-text/16987157/pubmed\" target=\"_blank\" id=\"16987157\">16987157</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8994 Version 173.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F187993\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F187994\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F188007\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F187997\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F187998\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F10909896\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F10909895\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F27102717\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F187974\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F187958\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F10909903\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11236626\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F187978\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F187977\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25722063\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F6842204\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F187965\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F187981\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F187962\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298971\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F187967\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F187990\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F187970\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F187985\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F21737065\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F187986\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F187972\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F187961\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F187980\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F187984\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F187987\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8994|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=carbidopa-and-levodopa-patient-drug-information\" class=\"drug drug_patient\">Carbidopa and levodopa: Patient drug information</a></li></ul></div></div>","javascript":null}